Positive CHMP opinion for Gohibic (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome – InflaRX
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)… read more.
